var data={"title":"Lorazepam: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lorazepam: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6480?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">see &quot;Lorazepam: Drug information&quot;</a> and <a href=\"topic.htm?path=lorazepam-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lorazepam: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49334833\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with opioids:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189926\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ativan;</li>\n      <li>LORazepam Intensol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50781432\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ativan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053736\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antianxiety Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anticonvulsant, Benzodiazepine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiemetic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Benzodiazepine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hypnotic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sedative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443858\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedation:</b> Limited data available: IV: 0.05 to 0.1 mg/kg/dose every 4 to 6 hours as needed (Cloherty 2012; Kliegman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus:</b> Limited data available: IV: 0.05 to 0.1 mg/kg slow IV over 2 to 5 minutes; may repeat in 10 to 15 minutes (AAP [Hegenbarth 2008]; Kliegman 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053729\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">see &quot;Lorazepam: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced nausea and vomiting, anticipatory:</b> Limited data available: Infants, Children, and Adolescents: Oral: 0.04 to 0.08 mg/kg/dose; maximum dose: 2 mg/dose; administer a dose the night before chemotherapy and again the next day prior to chemotherapy administration (Dupuis 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-associated nausea and vomiting, breakthrough:</b> Limited data available: Children and Adolescents: IV: 0.025 to 0.05 mg/kg/dose every 6 hours as needed; maximum dose: 2 mg/dose (Dupuis 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anxiety, acute:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;12 years: Limited data available: Oral, IV: Usual: 0.05 mg/kg/dose (maximum dose: 2 mg/dose) every 4 to 8 hours; range: 0.02 to 0.1 mg/kg/dose (Kliegman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral: 0.25 to 2 mg/dose 2 or 3 times daily; maximum dose: 2 mg/dose (Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Insomnia due to anxiety or stress:</b> Children &ge;12 years and Adolescents: Oral: Usual: 2 mg at bedtime; maximum: 4 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedation (preprocedure):</b> Limited data available: Children and Adolescents: Oral: Usual: 0.05 mg/kg; range reported in literature: 0.02 to 0.09 mg/kg (Burtles 1983; Henry 1991; Mundeleer 1980; Peters 1982). <b>Note:</b> In adults, the maximum dose is 4 mg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Status epilepticus:</b> Limited data available: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.05 to 0.1 mg/kg (maximum: 4 mg/dose) slow IV over 2 to 5 minutes; may repeat in 5 to 15 minutes if needed (AAP [Hegenbarth 2008]; NCS [Brophy 2012]; Kliegman 2007); usual total maximum dose: 8 mg (Crawford 1987; NICE 2012). <b>Note:</b> May be administered IM if IV not possible (AAP [Hegenbarth 2008]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intranasal: <b>Note:</b> Reserve for patients without IV access: 0.1 mg/kg/dose; maximum dose: 4 mg/dose (Ahmad 2006; Arya 2011; Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anxiety disorder:</b> Oral: Initial: 2 to 3 mg daily in 2 to 3 divided doses; usual dose: 2 to 6 mg daily in divided doses; however, daily dose may vary from 1 to 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Insomnia due to anxiety or stress:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;65 years: 0.5 to 2 mg at bedtime (Winkelman 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;65 years: 0.5 to 1 mg at bedtime (Winkelman 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> The manufacturer recommends higher dosing (ie, 2 to 4 mg at bedtime); however, generally, it is a safer approach to employ the above recommended doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Premedication for anesthesia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 0.05 mg/kg administered 2 hours before surgery; maximum dose: 4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.044 mg/kg administered 15 to 20 minutes before surgery; usual dose: 2 mg; maximum dose: 4 mg. <b>Note:</b> Doses &gt;2 mg should generally not be exceeded in patients &gt;50 years.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sublingual tablet [Canadian product]: 0.05 mg/kg 1 to 2 hours before surgery (maximum dose: 4 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Status epilepticus:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>American Epilepsy Society and Neurocritical Care Society recommendations:</i> 0.1 mg/kg (maximum dose: 4 mg) given at a maximum rate of 2 mg/minute; may repeat in 5 to 10 minutes (AES [Glauser 2016]; NCS [Brophy 2012]). <b>Note:</b> Dilute dose 1:1 with saline.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer's labeling:</i> 4 mg given slowly (2 mg/minute); may repeat in 10 to 15 minutes. May be given IM, but IV preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for lorazepam with concomitant medications</b>\n      <b>:</b> Children &ge;12 years and Adolescents: Probenecid or valproic acid: Reduce lorazepam dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Children &ge;12 years, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling; however, some clinicians recommend no dosage adjustments are necessary (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild to moderate impairment: No dosage adjustment necessary for acute doses; use repeated doses with caution; may increase the risk of propylene glycol toxicity. Monitor closely if using for prolonged periods of time or at high doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe impairment or failure: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children &ge;12 years, Adolescents, and Adults: No dosage adjustment necessary. For severe hepatic disease, use with caution; benzodiazepines may worsen hepatic encephalopathy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189896\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LORazepam Intensol: 2 mg/mL (30 mL) [alcohol free, dye free, sugar free; unflavored flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ativan: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL) [contains benzyl alcohol, polyethylene glycol, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/100 mL (100 mL); 100 mg/100 mL in NaCl 0.9% (100 mL); 60 mg/60 mL in NaCl 0.9% (60 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ativan: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ativan: 1 mg, 2 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg, 1 mg, 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189880\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189975\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49468920\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Ativan: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017794s044lbl.pdf&amp;token=Iam5bqtuLpuhJgT3VdiHUYlWaj8qFV36o/IJZx8ZKogdmhCKhS+2IqAAzAIpNLUin4XXyyRCUE4NcTDbFZ5I94kdHs1ykIu5iATe6SXgcZw=&amp;TOPIC_ID=12565\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017794s044lbl.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053741\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: May administer with food to decrease GI distress; dilute oral solution in water, juice, soda, or semisolid food (eg, applesauce, pudding).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intranasal: Administer undiluted (injectable formulation) into one nostril using a needleless syringe or nasal atomizer (Ahmad 2006; Anya 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Dilute prior to administration. Do not exceed 2 mg/minute or 0.05 mg/kg over 2 to 5 minutes; administer IV using repeated aspiration with slow IV injection, to make sure the injection is not intra-arterial and that perivascular extravasation has not occurred. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Administer undiluted by deep injection into muscle mass</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189918\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Intact vials should be refrigerated (room temperature storage information may be available; contact product manufacturer to obtain current recommendations). Protect from light. Parenteral admixture in D5W, LR, or NS is stable at room temperature (25&deg;C) for 24 hours (consult parenteral admixture resource for additional detail).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral concentrate: Store at colder room temperature or refrigerate at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Discard open bottle after 90 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet: Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual tablet [Canadian product]: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053740\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Management of anxiety disorders, short-term relief of symptoms of anxiety, anxiety associated with depressive symptoms (All indications: FDA approved in ages &ge;12 years and adults); has also been used for preprocedure sedation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment of status epilepticus (FDA approved in adults); preoperative sedation, anxiolytic and amnestic (FDA approved in adults); has also been used for breakthrough nausea and vomiting associated with chemotherapy </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189983\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">LORazepam may be confused with ALPRAZolam, clonazePAM, diazePAM, KlonoPIN, Lovaza, temazepam, zolpidem</p>\n        <p style=\"text-indent:0em;margin-left:2em;\">Ativan may be confused with Ambien, Atarax, Atgam, Avitene</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Lorazepam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) because of increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Injection dosage form contains propylene glycol. Monitor for toxicity when administering continuous or high-dose lorazepam infusions.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189980\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Aggressive behavior, agitation, akathisia, amnesia, anxiety, central nervous system stimulation, coma, disinhibition, disorientation, dizziness, drowsiness, dysarthria, euphoria, excitement, extrapyramidal reaction, fatigue, headache, hostility, hypothermia, irritability, mania, memory impairment, outbursts of anger, psychosis, sedation, seizures, sleep apnea (exacerbation), sleep disturbances, slurred speech, stupor, suicidal behavior, suicidal ideation, unsteadiness, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Changes in appetite, constipation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Change in libido, hyponatremia, SIADH</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Impotence, orgasm disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, anaphylactoid reaction, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Erythema at injection site, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Visual disturbances (including diplopia and blurred vision)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Apnea, exacerbation of obstructive pulmonary disease, hypoventilation, nasal congestion, respiratory depression, respiratory failure, worsening of sleep apnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abnormal gait, abnormal hepatic function tests, abnormality in thinking, acidosis, cardiac arrhythmia, ataxia, blood coagulation disorder, bradycardia, cardiac arrest, cardiac failure, cerebral edema, confusion, convulsions, cystitis, decreased mental acuity, delirium, depression, drug dependence (with prolonged use), drug toxicity (polyethylene glycol or propylene glycol poisoning [prolonged IV infusion]), excessive crying, gastrointestinal hemorrhage, hallucinations, hearing loss, heart block, hematologic abnormality, hepatotoxicity, hypertension, hyperventilation, hyporeflexia, infection, injection site reaction, myoclonus, neuroleptic malignant syndrome, paralysis, pericardial effusion, pheochromocytoma (aggravation), pneumothorax, pulmonary edema, pulmonary hemorrhage, pulmonary hypertension, seizure, tachycardia, urinary incontinence, ventricular arrhythmia, withdrawal syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189904\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to lorazepam, any component of the formulation, or other benzodiazepines (cross-sensitivity with other benzodiazepines may exist); acute narrow-angle glaucoma; severe respiratory insufficiency (except during mechanical ventilation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Additional contraindications: Hypersensitivity to polyethylene glycol, propylene glycol, or benzyl alcohol; sleep apnea; intra-arterial injection; use in premature infants</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Myasthenia gravis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189884\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug abuse: Risk of dependence increases in patients with a history of alcohol or drug abuse and those with significant personality disorders; use with caution in these patients. Tolerance, psychological and physical dependence may also occur with higher dosages and prolonged use. The risk of dependence is decreased with short-term treatment (2 to 4 weeks); evaluate the need for continued treatment prior to extending therapy duration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment, insufficiency, and/or encephalopathy. Dose adjustment (lower doses) may be needed. May worsen hepatic encephalopathy. Parenteral use is not recommended in patients with hepatic failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disorders: Preexisting depression may emerge or worsen during therapy. Not recommended for use in primary depressive or psychotic disorders. Should not be used in patients at risk for suicide without adequate antidepressant treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Parenteral use is not recommended in patients with renal failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease, including COPD or sleep apnea. Benzodiazepines may cause significant respiratory depression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concomitant use with opioids: <b>[US Boxed Warning]: </b><b>Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative </b><b>treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</b> In patients already receiving an opioid analgesic, prescribe a lower initial dose of lorazepam than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking lorazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in debilitated patients; initial doses should be at the lower end of dosing range.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: In pediatric and neonatal patients &lt;3 years, the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on the child's brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. Further studies are needed to fully characterize findings and ensure that these findings are not related to underlying conditions or the procedure itself. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (<a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm555631.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery&amp;token=YLy9c1sPZ/dHcqpzSuYgJdvuqUyvZWbMw+T4Q+fsbqW4JQlh3SbPN+UEnwg89nd5uWp4cid3WcHgE8E+YPsnho7ksvMXf2W/1bGGHC2/bOlcHBJNlxiua1RLIuBi4LS6hH0eJn6CRGL08achIDEibpee07SPOtQh1cHI+27+lhQ4jr1lNuZ0oUZfKxD9OHFT&amp;TOPIC_ID=12565\" target=\"_blank\">FDA 2016</a>).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polyethylene glycol: Parenteral formulation may contain polyethylene glycol. May be associated with toxicity in high-dose and/or longer-term therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Parenteral formulation may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling. May consider using enteral delivery of lorazepam tablets to decrease the risk of propylene glycol toxicity (Lugo 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Status epilepticus should not be treated with injectable benzodiazepines alone; requires close observation and management and possibly ventilatory support. When used as a component of preanesthesia, monitor for heavy sedation and airway obstruction; equipment necessary to maintain airway and ventilatory support should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypnotic: Appropriate use: As a hypnotic, should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7 to 10 days may indicate psychiatric or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance: Lorazepam is a short half-life benzodiazepine. Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance develops to the sedative, hypnotic, and anticonvulsant effects. It does not develop to the anxiolytic effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause acute withdrawal in patients receiving long-term benzodiazepine therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022456\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on the child's or fetus&rsquo; brain development and may contribute to various cognitive and behavioral problems; the FDA is requiring warnings be included in the manufacturer's labeling for all general anesthetic/sedative drugs. Multiple animal species studies have shown adverse effects on brain maturation; in juvenile animals, drugs that potentiate GABA activity and/or block NMDA receptors for &gt;3 hours demonstrated widespread neuronal and oligodendrocyte cell loss along with alteration in synaptic morphology and neurogenesis. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. Further studies are needed to fully characterize findings and ensure that these findings are not related to underlying conditions or the procedure itself. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use with caution in neonates, especially in preterm infants; several cases of neurotoxicity and myoclonus (rhythmic myoclonic jerking) have been reported. Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in pediatric/adolescent or psychiatric patients; discontinue drug if this occurs.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299616\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189889\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12565&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: May enhance the adverse/toxic effect of LORazepam. Specifically, prolonged stupor, respiratory depression, and/or hypotension.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of LORazepam.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May increase the serum concentration of LORazepam.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189908\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Lorazepam and its metabolite cross the human placenta. Teratogenic effects in humans have been observed with some benzodiazepines (including lorazepam); however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines (including lorazepam). Elimination of lorazepam in the newborn infant is slow; following in utero exposure, term infants may excrete lorazepam for up to 8 days (Bergman 1992; Iqbal 2002; Wikner 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053735\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory rate, blood pressure, heart rate; CBC with differential and liver function with long-term use; symptoms of anxiety; clinical signs of propylene glycol toxicity (for continuous high-dose and/or long duration intravenous use) including serum creatinine, BUN, serum lactate, and osmol gap</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189883\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189903\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Anticonvulsant: IV: Within 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypnosis: IM: 20 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sedation: IV: Within 2 to 3 minutes (Greenblatt 1983)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Anesthesia premedication: Adults: IM, IV: ~6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: IM: Rapid and complete absorption; Oral: Readily absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: IV: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 0.76 &plusmn; 0.37 L/kg (range: 0.14 to 1.3 L/kg) (McDermott 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (Chamberlain 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 months to &lt; 3 years: 1.62 L/kg (range: 0.67 to 3.4 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3 to &lt;13 years: 1.5 L/kg (range: 0.49 to 3 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">13 to &lt;18 years: 1.27 L/kg (range: 1 to 1.54 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 1.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~91%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; rapidly conjugated to lorazepam glucuronide (inactive)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Full-term neonates: IV: 40.2 &plusmn; 16.5 hours; range: 18 to 73 hours (McDermott 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric patients (Chamberlain 2012): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 months to &lt;3 years: 15.8 hours (range: 5.9 to 28.4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3 to &lt;13 years: 16.9 hours (range: 7.5 to 40.6 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">13 to &lt;18 years: 17.8 hours (range: 8.2 to 42 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Oral: ~12 hours; IV: ~14 hours; IM: ~13 to 18 hours (Greenblatt 1983); End-stage renal disease (ESRD): ~18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: IM: &le;3 hours; Oral: ~2 hours; Sublingual tablet [Canadian product]: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~88%; predominantly as inactive metabolites); feces (~7%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11446285\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Commercial oral solution is available (2 mg/mL)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Two different 1 mg/mL oral suspensions may be made from different generic lorazepam tablets (Mylan Pharmaceuticals or Watson Laboratories), sterile water, Ora-Sweet, and Ora-Plus.</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">Mylan tablets: Place one-hundred-eighty 2 mg tablets in a 12-ounce amber glass bottle; add 144 mL of sterile water to disperse the tablets; shake until slurry is formed. Add 108 mL Ora-Plus in incremental proportions; then add a quantity of Ora-Sweet sufficient to make 360 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 91 days when stored in amber glass prescription bottles at room temperature or refrigerated (preferred).</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">Watson tablets: Place one-hundred-eighty 2 mg tablets in a 12-ounce amber glass bottle; add 48 mL sterile water to disperse the tablets; shake until slurry is formed. Add 156 mL of Ora-Plus in incremental proportions; then add a quantity of Ora-Sweet sufficient to make 360 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Store in amber glass prescription bottles. Stable for 63 days at room temperature or 91 days refrigerated.</p>\n    <div class=\"reference\">Lee ME, Lugo RA, Rusho WJ, et al, &quot;Chemical Stability of Extemporaneously Prepared Lorazepam Suspension at Two Temperatures,&quot; <i>J Pediatr Pharmacol Ther</i>, 2004, 9(4):254-58.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189907\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (LORazepam Intensol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (30 mL): $48.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (LORazepam Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (30 mL): $48.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ativan Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (1 mL): $2.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $2.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LORazepam Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (1 mL): $2.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $2.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LORazepam-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 5% (100 mL): $50.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (LORazepam-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $49.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ativan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $2,798.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $3,737.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $5,956.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (LORazepam Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (100): $64.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $83.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $127.36</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189910\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abinol (CL);</li>\n      <li>Ansilor (PT);</li>\n      <li>Anta (TH);</li>\n      <li>Anxiar (RO);</li>\n      <li>Anxira (TH);</li>\n      <li>Anzepam (TW);</li>\n      <li>Aplacasse (AR);</li>\n      <li>Aripax (GR);</li>\n      <li>Ativan (AE, AU, BB, BF, BH, BJ, CI, CO, EG, ET, GB, GH, GM, GN, IE, IN, JO, KE, KR, KW, LR, MA, ML, MR, MT, MU, MW, MX, NE, NG, NZ, PE, PH, PK, QA, SA, SC, SD, SG, SL, SN, TN, TW, TZ, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Bonatranquan (DE);</li>\n      <li>Control (IT);</li>\n      <li>Donix (ES);</li>\n      <li>Emotival (AR);</li>\n      <li>Larpose (IN, LK);</li>\n      <li>Laubeel (DE);</li>\n      <li>Lauracalm (LU);</li>\n      <li>Lonza (TH);</li>\n      <li>Lopa (BD);</li>\n      <li>Lopam (TW);</li>\n      <li>Lora (CN);</li>\n      <li>Lorabenz (DK);</li>\n      <li>Lorafen (LV, PL);</li>\n      <li>Loram (HR);</li>\n      <li>Lorans (AE, BH, CY, EG, IQ, IR, IT, JO, KW, LB, LT, LY, MT, MY, OM, QA, SA, SY, YE);</li>\n      <li>Loranxil (HU);</li>\n      <li>Loravan (KR);</li>\n      <li>Lorax (BR);</li>\n      <li>Loraxen (BD);</li>\n      <li>Lorazep (TH);</li>\n      <li>Lorazepam-Efeka (LU);</li>\n      <li>Lorazepam-Eurogenerics (LU);</li>\n      <li>Lorazin (TW);</li>\n      <li>Lorenin (PT);</li>\n      <li>Loridem (BE, LU);</li>\n      <li>Lorivan (IL, MT, TR);</li>\n      <li>Lorsilan (HR);</li>\n      <li>Lozam (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Lozicum (BD, HK);</li>\n      <li>Merlit (AT, RU);</li>\n      <li>Merlopam (ID);</li>\n      <li>Nervistop L (AR);</li>\n      <li>Neuropam (TW);</li>\n      <li>Novhepar (GR);</li>\n      <li>Orfidal (ES);</li>\n      <li>Renaquil (ID);</li>\n      <li>Rilex (HU);</li>\n      <li>Sedatival (AR);</li>\n      <li>Sidenar (AR);</li>\n      <li>Silence (HK, TW);</li>\n      <li>Stapam (TW);</li>\n      <li>Tavor (BG, CZ, DE, GR, IT, TR);</li>\n      <li>Temesta (AT, BE, CH, DK, FI, FR, LU, NL, SE);</li>\n      <li>Titus (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, GR, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Tranqipam (ZA);</li>\n      <li>Trapax (AR, PY);</li>\n      <li>Trapex (BD, IN);</li>\n      <li>Vigiten (LU);</li>\n      <li>Zora (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahmad S, Ellis JC, Kamwendo H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial. <i>Lancet</i>. 2006;367(9522):1591-1597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/16698412 /pubmed\" target=\"_blank\" id=\"16698412 \">16698412 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson GD, Gidal BE, Kantor ED, et al, &ldquo;Lorazepam-Valproate Interaction: Studies in Normal Subjects and Isolated Perfused Rat Liver,&rdquo; <i>Epilepsia</i>, 1994, 35(1):221-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/8112251/pubmed\" target=\"_blank\" id=\"8112251\">8112251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 126, 182.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arya R, Gulati S, Kabra M, Sahu JK, Kalra V. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. <i>Epilepsia</i>. 2011;52(4):788-793.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/21275979 /pubmed\" target=\"_blank\" id=\"21275979 \">21275979 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bergman U, Rosa FW, Baum C, et al, &quot;Effects of Exposure to Benzodiazepine During Fetal Life,&quot; <i>Lancet</i>, 1992, 340(8821):694-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/1355799/pubmed\" target=\"_blank\" id=\"1355799\">1355799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brophy GM, Bell R, Claassen J, et al, &ldquo;Guidelines for the Evaluation and Management of Status Epilepticus,&rdquo; <i>Neurocrit Care</i>, 2012, 17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burtles R, Astley B. Lorazepam in children. A double-blind trial comparing lorazepam, diazepam, trimeprazine and placebo. <i>Br J Anaesth</i>. 1983;55(4):275-279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6132612/pubmed\" target=\"_blank\" id=\"6132612\">6132612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chamberlain JM, Capparelli EV, Brown KM, et al. Pharmacokinetics of intravenous lorazepam in pediatric patients with and without status epilepticus. <i>J Pediatr</i>. 2012;160(4):667-672.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22050870 /pubmed\" target=\"_blank\" id=\"22050870 \">22050870 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crawford TO, Mitchell WG, and Snodgrass SR, &ldquo;Lorazepam in Childhood Status Epilepticus and Serial Seizures: Effectiveness and Tachyphylaxis,&rdquo; <i>Neurology</i>, 1987, 37(2):190-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/3808299 /pubmed\" target=\"_blank\" id=\"3808299 \">3808299 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deshmukh A, Wittert W, Schnitzler E, et al, &ldquo;Lorazepam in the Treatment of Refractory Neonatal Seizures: A Pilot Study,&rdquo; <i>Am J Dis Child</i>, 1986, 140(10):1042-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/ 3752014 /pubmed\" target=\"_blank\" id=\" 3752014 \"> 3752014 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL and Nathan PC, &ldquo;Options for the Prevention and Management of Acute Chemotherapy-Induced Nausea and Vomiting in Children,&rdquo; <i>Paediatr Drugs</i>, 2003, 5(9):597-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/12956617/pubmed\" target=\"_blank\" id=\"12956617\">12956617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Robinson PD, Boodhan S, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2014;61(8):1506-1512. doi: 10.1002/pbc.25063.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/24753095/pubmed\" target=\"_blank\" id=\"24753095\">24753095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Federal Drug Administration. General Anesthetic and sedation drugs; drug safety communication - FDA approves label changes for use in young children. Food and Drug Administration website. <a href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm555631.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm555631.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>. Accessed July 6, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26900382\"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/26900382/pubmed\" target=\"_blank\" id=\"26900382\">26900382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenblatt DJ, Shader RI, and Abernethy DR. Drug therapy. Current status of benzodiazepines. <i>N Engl J Med</i>. 1983;309(6):354-358.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6135156/pubmed\" target=\"_blank\" id=\"6135156\">6135156</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &quot;Preparing for Pediatric Emergencies: Drugs to Consider,&quot; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henry DW, Burwinkle JW, and Klutman NE, &ldquo;Determination of Sedative and Amnestic Doses of Lorazepam in Children,&rdquo; <i>Clin Pharm</i>, 1991, 10(8):625-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/1934919/pubmed\" target=\"_blank\" id=\"1934919\">1934919</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iqbal MM, Sobhan T, Ryals T, et al, &quot;Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,&quot; <i>Psychiatr Serv</i>, 2002, 53(1):39-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/11773648/pubmed\" target=\"_blank\" id=\"11773648\">11773648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S, Blajchman A, Stephenson M, et al, &quot;Prospective Follow-Up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication,&quot; <i>Am J Obstet Gynecol</i>, 1993, 168(5):1393-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/8498418/pubmed\" target=\"_blank\" id=\"8498418\">8498418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. <i>J Pediatr</i>. 2012;161(3):448-451.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22504099/pubmed\" target=\"_blank\" id=\"22504099\">22504099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee DS, Wong HA, and Knoppert DC, &ldquo;Myoclonus Associated With Lorazepam Therapy in Very-Low-Birth-Weight Infants,&rdquo; <i>Biol Neonate</i>, 1994, 66(6):311-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/7727612/pubmed\" target=\"_blank\" id=\"7727612\">7727612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lemmer P, Schneider S, M&uuml;he A, Wennig R. Quantification of lorazepam and lormetazepam in human breast milk using GC-MS in the negative chemical ionization mode. <i>J Anal Toxicol</i>. 2007;31(4):224-226.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/17555647/pubmed\" target=\"_blank\" id=\"17555647\">17555647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lorazepam injection [prescribing information]. Eatontown, NJ: West-ward Pharmaceuticals; June 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lorazepam solution concentrate [prescribing information]. Columbus, OH: Roxane Laboratories, Inc; October 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lorazepam tablets [prescribing information]. Columbus, OH: American Health Packaging.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lugo RA, Chester EA, Cash J, et al, &ldquo;A Cost Analysis of Enterally Administered Lorazepam in the Pediatric Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 1999, 27(2):417-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/10075070/pubmed\" target=\"_blank\" id=\"10075070\">10075070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall JD, Farrar HC, and Kearns GL, &ldquo;Diarrhea Associated With Enteral Benzodiazepine Solutions,&rdquo; <i>J Pediatr</i>, 1995, 126(4):657-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/7699551/pubmed\" target=\"_blank\" id=\"7699551\">7699551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDermott CA, Kowalczyk AL, Schnitzler ER, et al, &ldquo;Pharmacokinetics of Lorazepam in Critically Ill Neonates With Seizures,&rdquo; <i>J Pediatr</i>, 1992, 120(3):479-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/1538303/pubmed\" target=\"_blank\" id=\"1538303\">1538303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mundeleer P. Child premedication per os with lorazepam. <i>Acta Anaesthesiol Belg</i>. 1980;(31 Suppl):187-193.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6109421/pubmed\" target=\"_blank\" id=\"6109421\">6109421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Care Excellence (NICE). Diagnosis and management of ethe epilepsies in adults and children. January 2012. Available at http://www.nice.org.uk/nicemedia/live/13635/57779/57779.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peters CG, Brunton JT. Comparative study of lorazepam and trimeprazine for oral premedication in paediatric anaesthesia. <i>Br J Anaesth</i>. 1982;54(6):623-628.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6123337/pubmed\" target=\"_blank\" id=\"6123337\">6123337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Relling MV, Mulhern RK, Dodge RK, et al. Lorazepam pharmacodynamics and pharmacokinetics in children. <i>J Pediatr</i>. 1989;114(4 Pt 1):641-646.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/2926577 /pubmed\" target=\"_blank\" id=\"2926577 \">2926577 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective gaba(a) receptor modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:1-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/22536226/pubmed\" target=\"_blank\" id=\"22536226\">22536226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. <i>Br Med J (Clin Res Ed)</i>. 1981;282(6270):1106-1108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/6113019/pubmed\" target=\"_blank\" id=\"6113019\">6113019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wikner BN, Stiller CO, Bergman U, et al, &quot;Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,&quot; <i>Pharmacoepidemiol Drug Saf</i>, 2007, 16(11):1203-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/17894421/pubmed\" target=\"_blank\" id=\"17894421\">17894421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26444730\"></a>Winkelman JW. Clinical Practice. Insomnia Disorder. <i>N Engl J Med</i>. 2015 Oct 8;373(15):1437-1444.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/26444730/pubmed\" target=\"_blank\" id=\"26444730\">26444730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lorazepam-pediatric-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12565 Version 241.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F49334833\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F189926\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50781432\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053736\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443858\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053729\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F189896\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F189880\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F189975\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F49468920\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053741\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F189918\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053740\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F189983\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F189980\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F189904\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F189884\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022456\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299616\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F189889\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F189908\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053735\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F189883\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F189903\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F11446285\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F189907\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F189910\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12565|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lorazepam-drug-information\" class=\"drug drug_general\">Lorazepam: Drug information</a></li><li><a href=\"topic.htm?path=lorazepam-patient-drug-information\" class=\"drug drug_patient\">Lorazepam: Patient drug information</a></li></ul></div></div>","javascript":null}